Pharm-Olam provided a full-service solution for two Phase II, dose escalation allergy studies, Grass Pollen & Birch Pollen.
FEBRUARY 1, 2014
Pharm-Olam was contracted to provide a full-service solution for two Phase II, dose escalation allergy studies that required a total of 500 patients in Europe. With two different allergy indications, Grass Pollen and Birch Pollen, these studies presented some unique challenges.